We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Siemens Healthineers and Primary Health Care Enter Contract for In Vitro Diagnostics

By LabMedica International staff writers
Posted on 12 Nov 2018
Siemens Healthineers (Erlangen, Germany) has entered into a strategic partnership with Australian integrated healthcare provider Primary Health Care to deploy more than 70 Atellica Solution immunoassay and clinical chemistry analyzers, marking the largest contract ever for in vitro diagnostics testing in the country. More...


The analyzers are integrated with Atellica Diagnostics IT solutions and will connect to the company’s strategic partner Inpeco’s FlexLab track for total lab automation to deliver a high throughput multi-disciplinary solution with capabilities that are transforming the clinical laboratory landscape across Australia.

Siemens Healthineers offers a wide portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Primary Health Care has a large presence in all mainland states in Australia with one in every three pathology samples taken in the country being tested in a Primary laboratory. The Siemens Healthineers technology will be rolled out in New South Wales, Queensland, Victoria and Western Australia.

The strategic engagement couples Primary’s expansive network of more than 2,300 national pathology collection sites with workflow improvement and expanded clinical capabilities from Siemens Healthineers to establish a new level of automated diagnostic delivery. Through deep analytics, and intelligent data and process management, Atellica Diagnostics IT software will provide Primary with improved visibility, flexibility and control over its entire operation. Siemens Healthineers and Inpeco SA will deliver this fully automated multidisciplinary solution that will vastly simplify clinical and operational workflows and help Primary achieve better outcomes at much lower costs.

“With the introduction of the Atellica Solution and the complementary, innovative offering of Atellica Diagnostics IT, we’ll turn what has been more than a decade of collaboration with Primary Health Care into an entirely new frontier for the Australian pathology industry,” said Sebastian D’Angelo, General Manager, Laboratory Diagnostics, Australia, Siemens Healthineers.

“This new collaboration will allow us to take Primary’s operational efficiencies to new heights,” said Wes Lawrence, Chief Executive of Pathology at Primary Health Care. “Thanks to this next-generation technology, we’re able to increase productivity, and focus more on value-adding lab activities and less on sample and instrument handling. In doing so, processes will be reduced and testing quality will be advanced, ultimately helping us increase cost savings and focus on the human impact of our work.”


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.